Skillz Inc. (SKLZ) came out with a quarterly loss of $0.92 per share versus the Zacks Consensus Estimate of a loss of $1.09. This compares to loss of $1.45 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 15.60%. A quarter ago, it was expected that this company would post a loss of $1.07 per share when it actually produced a loss of $1.50, delivering a surprise of -40.19%.Over the last four quarters, the company has surpassed c ...

Willdan Group (WLDN) came out with quarterly earnings of $0.63 per share, beating the Zacks Consensus Estimate of $0.44 per share. This compares to earnings of $0.40 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 43.18%. A quarter ago, it was expected that this energy efficiency and sustainability consultant would post earnings of $0.57 per share when it actually produced earnings of $0.75, delivering a surprise of 31.58%.Ove ...

PDF Solutions (PDFS) came out with quarterly earnings of $0.21 per share, beating the Zacks Consensus Estimate of $0.19 per share. This compares to earnings of $0.15 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 10.53%. A quarter ago, it was expected that this provider of software and services for semiconductor makers would post earnings of $0.24 per share when it actually produced earnings of $0.25, delivering a surprise of ...

Assembly Biosciences (ASMB) came out with a quarterly loss of $1.17 per share versus the Zacks Consensus Estimate of a loss of $2.01. This compares to loss of $1.66 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 41.79%. A quarter ago, it was expected that this biotech drug developer would post a loss of $1.75 per share when it actually produced a loss of $1.57, delivering a surprise of 10.29%.Over the last four quarters, the ...

Company Performance - Crinetics Pharmaceuticals reported a quarterly loss of $1.04 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.99, and compared to a loss of $0.93 per share a year ago, indicating a decline in performance [1] - The company posted revenues of $0.36 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 261%, but this was a decrease from year-ago revenues of $0.64 million [2] - Over the last four quarters, Crinetics has only surpassed consensus EPS estimates once, indicating inconsistent performance [2] Stock Movement and Outlook - Crinetics Pharmaceuticals shares have declined approximately 38.6% since the beginning of the year, significantly underperforming the S&P 500, which declined by only 4.3% [3] - The company's earnings outlook is uncertain, with current consensus EPS estimates for the upcoming quarter at -$1.10 on revenues of $2.6 million, and for the current fiscal year at -$4.33 on revenues of $5.63 million [7] Industry Context - The Medical - Drugs industry, to which Crinetics belongs, is currently ranked in the top 26% of over 250 Zacks industries, suggesting a relatively strong industry performance [8] - The performance of Crinetics may be influenced by the overall outlook for the industry, as empirical research indicates that the top 50% of Zacks-ranked industries outperform the bottom 50% by more than 2 to 1 [8]

Iovance Biotherapeutics (IOVA) came out with a quarterly loss of $0.36 per share versus the Zacks Consensus Estimate of a loss of $0.25. This compares to loss of $0.42 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -44%. A quarter ago, it was expected that this biotechnology company would post a loss of $0.27 per share when it actually produced a loss of $0.26, delivering a surprise of 3.70%.Over the last four quarters, the c ...

Company Performance - Flux Power Holdings, Inc. reported a quarterly loss of $0.12 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.09, but an improvement from a loss of $0.16 per share a year ago, indicating a surprise of -33.33% [1] - The company posted revenues of $16.74 million for the quarter ended March 2025, exceeding the Zacks Consensus Estimate by 2.62% and showing an increase from $14.46 million in the same quarter last year [2] - Over the last four quarters, Flux Power has not surpassed consensus EPS estimates, but it has topped consensus revenue estimates twice [2] Stock Performance - Flux Power shares have increased by approximately 20.9% since the beginning of the year, contrasting with a decline of -4.3% in the S&P 500 [3] - The company's current consensus EPS estimate for the upcoming quarter is -$0.06 on revenues of $16.61 million, and for the current fiscal year, it is -$0.36 on revenues of $65.9 million [7] Industry Outlook - The Electronics - Miscellaneous Products industry, to which Flux Power belongs, is currently ranked in the bottom 40% of over 250 Zacks industries, suggesting potential challenges ahead [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which could impact Flux Power's stock performance [5]

Pacira (PCRX) came out with quarterly earnings of $0.62 per share, beating the Zacks Consensus Estimate of $0.57 per share. This compares to earnings of $0.62 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 8.77%. A quarter ago, it was expected that this specialty drugmaker would post earnings of $0.86 per share when it actually produced earnings of $0.91, delivering a surprise of 5.81%.Over the last four quarters, the company ...

Insulet (PODD) came out with quarterly earnings of $1.02 per share, beating the Zacks Consensus Estimate of $0.81 per share. This compares to earnings of $0.73 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 25.93%. A quarter ago, it was expected that this maker of insulin infusion systems would post earnings of $1.05 per share when it actually produced earnings of $1.15, delivering a surprise of 9.52%.Over the last four quart ...

Texas Roadhouse (TXRH) came out with quarterly earnings of $1.70 per share, missing the Zacks Consensus Estimate of $1.75 per share. This compares to earnings of $1.69 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -2.86%. A quarter ago, it was expected that this restaurant chain would post earnings of $1.66 per share when it actually produced earnings of $1.73, delivering a surprise of 4.22%.Over the last four quarters, the ...